NGR peptide is a tripeptide containing the Asn-Gly-Arg (NGR) motif, can bind to both CD13 and RGD binding integrin[1]. NGR peptide can rapidly convert to isoaspartate-glycine-arginine (isoDGR) by asparagine deamidation, generating αvβ3 ligands[2]. NGR peptide can be labeled with 99mTc to be used as an imaging agent for observing the distribution of characteristic molecules in the body of animals[3]. NGR peptide can be conjugated with anti-cancer drugs and be targeted for delivery to tumor cells, thereby inhibiting the progression of tumors[4]. NGR peptide can be used as a capture probe to modify TiO₂ nanofiber substrates to selectively enrich and isolate circulating tumor cells[5].
References:
[1] Wang R E, Niu Y, Wu H, et al. Development of NGR peptide-based agents for tumor imaging[J]. American journal of nuclear medicine and molecular imaging, 2011, 1(1): 36.
[2] Bieker R, Kessler T, Schwöppe C, et al. Infarction of tumor vessels by NGR-peptide–directed targeting of tissue factor: experimental results and first-in-man experience[J]. Blood, The Journal of the American Society of Hematology, 2009, 113(20): 5019-5027.
[3] Corti A, Curnis F. Tumor vasculature targeting through NGR peptide-based drug delivery systems[J]. Current pharmaceutical biotechnology, 2011, 12(8): 1128-1134.
[4] Enyedi K N, Tóth S, Szakács G, et al. NGR-peptide-drug conjugates with dual targeting properties[J]. PLoS One, 2017, 12(6): e0178632.
[5] Chen C, Wu Z, Ding P, et al. Peptide NGR modified TiO2 nanofiber substrate for circulating tumor cells capture[J]. Advanced Fiber Materials, 2020, 2(4): 186-193.